A non-profit pharmaceutical company for the cancers markets ignore
Build a drug company that does not need profits, modelled on the ones that developed new tuberculosis and sleeping-sickness drugs, to take on rare, paediatric and undruggable cancers.
A product development partnership (PDP) for oncology, on the model of the Drugs for Neglected Diseases initiative, TB Alliance and Medicines for Malaria Venture: philanthropic and public core funding, in-licensing of shelved or academic assets, virtual development through contract organisations, trials run with academic networks, and pricing at cost plus a margin reinvested in the pipeline. Target areas are those where the commercial case is weak but the science is ready: paediatric solid tumours, rare fusion-driven cancers, repurposed generics, and de-escalation regimens. The PDP can also be the licensee of last resort for assets that companies abandon.
- Incentives reward me-too drugs and marginal gains · The system pays the same for a drug that adds two months as for a cure, so companies race to copy rather than to cure.
- Rare and paediatric cancers without markets · Taken together rare cancers are a fifth of all cancers, but each one alone is too small for a company to invest in.
- The valley of death between lab and product · Most academic discoveries die before anyone tests them in people because nobody funds the middle step.
Pages like this
not linked directly; found by shared links- IdeaEscrow a share of adult revenue until the paediatric study is done
Shares Advance market commitments for paediatric and rare cancer drugs, Neuroblastoma (paediatric), Incentives reward me-too drugs and marginal gains, Rare and paediatric cancers without markets.
- IdeaPay a prize for rare cancer drugs instead of hoping for a market
Shares Neuroblastoma (paediatric), Incentives reward me-too drugs and marginal gains, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaA diversified royalty pool that finances academic phase 1 trials across fifty assets
Shares Milestone-based venture philanthropy with royalties recycled into the pipeline, The valley of death between lab and product, Incentives reward me-too drugs and marginal gains.
- IdeaAn open organoid bank for cancers too rare to have models
Shares Biliary tract cancer (cholangiocarcinoma), Neuroblastoma (paediatric), Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaAn open model bank for the rare tumours nobody has models for
Shares The valley of death between lab and product, Biliary tract cancer (cholangiocarcinoma), Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaOpen-source drug discovery to clinical proof of concept for neglected cancers
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaAn international consortium pooling the outcome of every treated child with cancer
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaTrial-in-a-box: a preconfigured protocol kit any hospital can open for a rare cancer
Shares Biliary tract cancer (cholangiocarcinoma), Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).